

## Epigenetic mechanisms elicited by nutrition in early life

Roberto Berni Canani<sup>1,2\*</sup>, Margherita Di Costanzo<sup>1</sup>, Ludovica Leone<sup>1</sup>, Giorgio Bedogni<sup>2,3,4</sup>, Paolo Brambilla<sup>2,5</sup>, Stefano Cianfarani<sup>2,6</sup>, Valerio Nobili<sup>2,7</sup>, Angelo Pietrobelli<sup>2,8</sup> and Carlo Agostoni<sup>2,4</sup>

<sup>1</sup>Department of Pediatrics and European Laboratory for the Investigation of Food Induced Diseases, University of Naples 'Federico II', Naples, Italy

<sup>2</sup>'The Hobbit Group'

<sup>3</sup>Clinical Epidemiology Unit, Liver Research Center, Basovizza, Trieste, Italy

<sup>4</sup>Institute of Pediatrics, University of Milan, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Milan, Italy

<sup>5</sup>ASL Milano 2, Milan, Italy

<sup>6</sup>Molecular Endocrinology Unit-DPUO, Bambino Gesù Children's Hospital-'Rina Balducci' Center of Pediatric Endocrinology, Tor Vergata University, Rome, Italy

<sup>7</sup>Metabolic and Autoimmunity Liver Unit, Bambino Gesù Children's Hospital, Rome, Italy

<sup>8</sup>Pediatric Unit, Verona University Medical School, Verona, Italy

### Abstract

A growing number of studies focusing on the developmental origin of health and disease hypothesis have identified links among early nutrition, epigenetic processes and diseases also in later life. Different epigenetic mechanisms are elicited by dietary factors in early critical developmental ages that are able to affect the susceptibility to several diseases in adulthood. The studies here reviewed suggest that maternal and neonatal diet may have long-lasting effects in the development of non-communicable chronic adulthood diseases, in particular the components of the so-called metabolic syndrome, such as insulin resistance, type 2 diabetes, obesity, dyslipidaemia, hypertension, and CVD. Both maternal under- and over-nutrition may regulate the expression of genes involved in lipid and carbohydrate metabolism. Early postnatal nutrition may also represent a vital determinant of adult health by making an impact on the development and function of gut microbiota. An inadequate gut microbiota composition and function in early life seems to account for the deviant programming of later immunity and overall health status. In this regard probiotics, which have the potential to restore the intestinal microbiota balance, may be effective in preventing the development of chronic immune-mediated diseases. More recently, the epigenetic mechanisms elicited by probiotics through the production of SCFA are hypothesised to be the key to understand how they mediate their numerous health-promoting effects from the gut to the peripheral tissues.

**Key words:** Epigenome: Microbiota: Maternal nutrition: Adult metabolic diseases

### Introduction

During the last few years, a growing number of studies focusing on the developmental origin of health and disease have identified links among early nutrition, epigenetic processes and diseases also in later life. There is convincing experimental evidence to suggest that epigenetic marks serve as a memory of exposure in early life to inadequate or inappropriate nutritional factors. These marks induce long-term changes in gene expression, potentially leading to diseases in adulthood, according to the 'developmental origin of health and disease' (known as DOHaD) hypothesis<sup>(1–3)</sup>. Epigenetic modifications may be one mechanism by which exposure to an altered intra-uterine milieu or

metabolic perturbation may influence gene expression and modulate the phenotype of the organism much later in life<sup>(4)</sup>. Exposures during early life may be critical, as the plasticity of growing and developing tissues means that they shape the way in which the body responds to later challenges.

The purpose of this review is to present the latest scientific data suggesting that nutrition in early life could be considered as an important risk factor for non-communicable diseases of adulthood. In this regard, the role of intestinal microflora and its metabolites, such as SCFA and especially butyrate, will be addressed. Probiotics are largely used in human nutrition, especially in the paediatric age. Many

**Abbreviations:** CpG, cytosine–phosphate–guanine; H3K9, histone H3 lysine 9; HDAC, histone deacetylase; IUGR, intra-uterine growth retardation; JHDM2a, JmjC-domain-containing histone demethylase 2A; miRNA, microRNAs; Pdx-1, pancreatic and duodenal homeobox 1.

\*Corresponding author: Dr Roberto Berni Canani, fax +39 0815451278, email [berni@unina.it](mailto:berni@unina.it)

infant formulas, and other baby food products contain probiotics. The possible presence of probiotic strains even in human milk is debated too. It is hypothesised that the biological function of probiotics may be the result of epigenetic modifications that may explain the wide range of the observed effects.

### Epigenetic mechanisms elicited by nutritional factors

Epigenetics encompasses changes to marks on the genome that are copied from one cell generation to the next, which may alter gene expression, but which do not involve changes in the primary DNA sequence. There are three distinct, but closely inter-acting, epigenetic mechanisms possibly elicited by nutritional factors (Table 1). They include DNA methylation, histone modifications and non-coding microRNAs (miRNA; short RNA molecules) which, together, are responsible for regulating the intensity and the timing of expression of specific genes, not only during cellular differentiation in embryonic and fetal development but also throughout the life-course<sup>(5,6)</sup>.

#### Effects of nutritional factors on DNA methylation

Changes in DNA methylation are an essential part of normal development. Nutritional factors can change DNA methylation of gene specific promoters, which are closely associated with gene expression. A proportion of the cytosine residues is modified after translation by attachment of a methyl group to position 5 on the cytosine ring. Such methylated cytosines are usually found where the cytosine is next to a guanine residue, i.e. in a cytosine–phosphate–guanine (CpG) dinucleotide. In about half the genes of human genome, unmethylated CpG are found clustered

at the 5' ends of genes in domains known as CpG islands. When the CpG in such islands are unmethylated, gene transcription proceeds normally but when some or all of the CpG become methylated, the genes are switched off<sup>(7)</sup>.

Folate has been extensively studied for its effect on DNA methylation, because folate carries a methyl group and ultimately delivers this methyl group for the synthesis of adenosyl methionine (AdoMet), the unique methyl donor for DNA methylation reactions. However, folate is not the unique determinant of DNA methylation, because other methyl donor nutrients such as methionine, choline, betaine, and vitamins B<sub>2</sub>, B<sub>6</sub> and B<sub>12</sub> can also change DNA methylation status<sup>(8)</sup>. Because folate deficiency during pregnancy is associated with an increased risk of neural tube defects, aberrant reprogramming of DNA methylation by low dietary folate has been suggested as a candidate mechanism. In an animal study, restriction of folate, vitamin B<sub>12</sub> and methionine from the periconceptual diet induced obesity in adult offspring and an altered immune responses to an antigenic challenge<sup>(9)</sup>. However, periconceptual supplementation of folic acid is associated with imprinting status of insulin-like growth factor 2 in the child, which may affect intra-uterine growth with potential consequences in adulthood as illustrated by the association between higher insulin-like growth factor 2 methylation and decreased birth weight<sup>(10)</sup>. Choline and betaine, two donors of methyl groups, have been studied for their role upon brain development and function. Zeisel<sup>(11)</sup> demonstrated that choline availability during fetal brain development induces epigenetic changes that can finely modulate the expression of genes with specific roles in neuronal differentiation and angiogenesis in the fetal hippocampus<sup>(11,12)</sup>. Dietary restriction in methyl donors as well as genetic polymorphisms in folate metabolism have

**Table 1.** Epigenetic roles of main nutritional factors and type of diets

Nutritional factors (natural source) and diet	Epigenetic mechanisms	Main physiological and clinical effects	References
Butyrate (fermentation of dietary fibre)	Histone modifications	Cancer prevention and therapy; anti-inflammatory	Wiedmeier <i>et al.</i> <sup>(55)</sup>
Betaine (grain products and vegetables such as spinach and beets) Choline (red meat, poultry, milk, eggs)	DNA methylation	Fetal brain development and function	Sinclair <i>et al.</i> <sup>(10)</sup> , Zeisel <sup>(11)</sup> , Mehedint <i>et al.</i> <sup>(12)</sup> , Kanai & Hirohashi <sup>(13)</sup>
Curcumin (turmeric)	MicroRNAs	Cancer prevention and therapy	Salerno <i>et al.</i> <sup>(22)</sup> , Sun <i>et al.</i> <sup>(23)</sup>
Diallyl disulfide (garlic)	Histone modifications	Cancer prevention	Ficz <i>et al.</i> <sup>(15)</sup> , Delage & Dashwood <sup>(16)</sup>
High-cholesterol diet	MicroRNAs	Obesity	Pogribny <i>et al.</i> <sup>(26)</sup>
High-fat diet	DNA methylation	Obesity; metabolic syndrome	Buckley <i>et al.</i> <sup>(45)</sup> , Khan <i>et al.</i> <sup>(46,47)</sup>
Dietary methyl deficiency	MicroRNAs	Non-alcoholic steatohepatitis; liver cancer	Weiss <i>et al.</i> <sup>(25)</sup>
Dietary protein restriction	DNA methylation; histone modifications	Impaired glucose metabolism; type 2 diabetes	Armitage <i>et al.</i> <sup>(31,32)</sup> , Cianfarani <i>et al.</i> <sup>(40)</sup>
Folic acid (leafy vegetables, nuts, sunflower, seeds)	DNA methylation	Embryonic development	Steegers-Theunissen <i>et al.</i> <sup>(9)</sup>
Genistein (soya)	MicroRNAs	Cancer prevention and therapy	Iorio <i>et al.</i> <sup>(21)</sup>
Retinoic acid (carrots, spinach, eggs)	Histone modifications; microRNAs	Cancer prevention and therapy	Yang <i>et al.</i> <sup>(24)</sup>
Sulforaphane (broccoli)	Histone modifications	Cancer prevention	Ficz <i>et al.</i> <sup>(15)</sup> , Delage & Dashwood <sup>(16)</sup>

been associated with abnormal DNA methyltransferase expression, global DNA hypomethylation and increased cancer risk<sup>(13)</sup>. Using the agouti viable yellow (Avy) mouse model, Waterland<sup>(14)</sup> have also shown that methyl donor supplementation prevents transgenerational amplification of obesity through three generations, suggesting a role for DNA methylation in the developmental establishment of body-weight regulation. All these studies suggest that DNA methylation induced by nutritional factors in early life could play a critical role in development regulation not only during the fetal period but also throughout the life-course. The new research reveals that a new type of epigenetic modification, 5-hydroxymethylcytosine, plays a critical role mediating the external signals that instruct a cell how to develop. Hydroxymethylation appears to be linked to a higher degree of pluripotency, and the balance between hydroxymethylation and methylation in the genome is inextricably linked with the balance between pluripotency and lineage commitment. This new epigenetic mark, hydroxymethylation, might help with developing improved strategies for regenerative medicine<sup>(15)</sup>.

#### *Effects of nutritional factors on histone modifications*

In contrast to DNA that is modified only by methylation, histones can be modified by methylation, acetylation, phosphorylation, biotinylation, ubiquitination and ADP-ribosylation, which are different types of chemical modifications mainly located within the N-terminal tails of core histones. Histone acetylation is one of the most extensively studied epigenetic mechanisms. Histone tail acetylation is believed to enhance the accessibility of a gene to the transcription machinery, whereas deacetylated tails are highly charged and believed to be tightly associated with the DNA backbone, thus limiting accessibility of genes to transcription factors<sup>(16)</sup>. Interestingly, histone deacetylase (HDAC) inhibitors have been recognised as new potential therapeutic drugs against cancer, because they induce cell cycle arrest and apoptosis by enhancing the expression of certain pro-apoptotic or cell cycle-mediating genes. Recent interest in HDAC inhibitors has expanded into the realm of cancer chemoprevention, as distinct from cancer therapy, with evidence that dietary compounds such as butyrate, diallyl disulfide and sulforaphane act as weak ligands for HDAC and exhibit HDAC inhibitory activity. The working hypothesis for dietary agents is that DNA/chromatin interactions are kept in a constrained state in the presence of HDAC/co-repressor complexes, but HDAC inhibitors enable histone acetyltransferase/co-activator (HAT/CoA) complexes to transfer acetyl groups to lysine 'tails' in histones, thereby loosening the interactions with DNA and facilitating transcription factor access and gene activation. Among the epigenetically silenced genes that have received particular interest are p21 and bax due to their implications for cell cycle arrest and apoptosis, and

because they are among a select cadre of genes frequently repressed in cancer cells and de-repressed following treatment with HDAC inhibitors.

Different dietary agents such as butyrate, biotin, lipoic acid, garlic organosulfur compounds, and metabolites of vitamin E have structural features compatible with HDAC inhibition. The ability of dietary compounds to de-repress epigenetically silenced genes in cancer cells, and to activate these genes in normal cells, has important implications for cancer prevention and therapy<sup>(17)</sup>. In a broader context, there is growing interest in dietary HDAC inhibitors and their impact on epigenetic mechanisms affecting other chronic conditions, such as CVD, neurodegeneration and ageing.

#### *Effects of nutritional factors on microRNAs*

RNA is not only a messenger operating between DNA and protein. Transcription of the entire eukaryotic genome generates a myriad of non-protein-coding RNA species that show complex overlapping patterns of expression and regulation. miRNA are small RNA molecules encoded in the genome that can have a profound effect in controlling gene expression. miRNA bind to their target mRNA and down-regulate their stabilities and/or translation. Each miRNA is predicted to have many targets, and each mRNA may be regulated by more than one miRNA<sup>(18,19)</sup>. miRNA can play important roles in controlling DNA methylation and histone modifications, creating a highly controlled feedback mechanism<sup>(20)</sup>. Interestingly, epigenetic mechanisms such as promoter methylation or histone acetylation can also modulate miRNA expression. A relationship between epigenetics and miRNA has been found to play important roles in carcinogenesis by altering cell proliferation and apoptosis<sup>(21)</sup>. Curcumin, genistein and retinoic acid are bioactive food components which are able to reduce carcinogenesis through miRNA<sup>(22–25)</sup>. More recently, it has been suggested that miRNA are involved not only in carcinogenesis, but also in the genesis of insulin resistance and other related disorders. Animal models of methyl-deficient diet suggest that alterations in the expression of miRNA are a fundamental event during the development of liver cancer and non-alcoholic steatohepatitis induced by dietary methyl deficiency<sup>(26)</sup>. Alterations of miRNA are also observed in pigs fed a high-cholesterol diet compared with those fed a standard diet, indicating the potential implications of miRNA in obesity<sup>(27)</sup>. Although long non-coding RNA are among the least well understood of non-protein-coding RNA species, they cannot all be dismissed as merely transcriptional 'noise'. Recent evidence suggests their roles in transcriptional regulation, epigenetic gene regulation and diseases<sup>(28)</sup>. In this area, more studies are needed to evaluate the therapeutic potential of epigenetic modifiers and non-protein-coding RNA species.

### Epigenetic mechanisms elicited by maternal diet during pregnancy

Epidemiological and experimental data obtained in animal models<sup>(29–32)</sup> show that both under- and over-nutrition during pregnancy and/or lactation induce stable alterations to the physiological and structural phenotype of the offspring. Studies in animal models have used a candidate gene approach to identify the molecular basis for changes in activities of metabolic and endocrine pathways, with a specific focus on corticosteroid activity, and carbohydrate and lipid metabolism.

In rats moderate maternal dietary protein restriction is known to alter phenotypes in the offspring, which manifests as hypertension, dyslipidaemia and impaired glucose metabolism. However, these abnormalities can be reversed by folate supplementation. It has been shown that the induction of an altered phenotype by a maternal protein-restricted diet during pregnancy involves changes in DNA methylation and histone modifications in specific genes, including the glucocorticoid receptor (33% lower;  $P < 0.001$ ) and PPAR $\alpha$  (26% lower;  $P < 0.05$ ) in the liver of juvenile and adult offspring<sup>(33,34)</sup>, as well as hepatocyte nuclear factor 4a (Hnf4a) in pancreatic islets<sup>(35)</sup>. However, a high protein intake in rats during pregnancy and lactation also results in male offspring with higher blood pressure and female offspring with higher body mass and increased fat pad mass; it is possible to speculate that these effects are also mediated by epigenetic mechanisms<sup>(36)</sup>.

Maurer & Reimer<sup>(37)</sup> showed that a maternal high-protein diet, but not high-prebiotic fibre diet, during pregnancy and lactation could negatively influence the expression of genes involved in glucose and lipid metabolism in the offspring rats. These early changes, perhaps based on epigenetic mechanisms, could have long-term consequences for the development of obesity and the metabolic syndrome<sup>(37)</sup>.

Interestingly, a number of clinical studies have shown that the highest risk for development of the metabolic syndrome and diabetes occurs in adults who are born small for gestational age and become overweight in early childhood. The association between low birth weight and early postnatal catch up growth with late onset of disease is due to very early development of insulin resistance<sup>(38–40)</sup>. In experimental animal studies there is evidence that prenatal under-nutrition causes alteration in pancreatic islet neogenesis, impairing the capacity of  $\beta$ -cell regeneration<sup>(41)</sup>. This may explain the inability of  $\beta$ -cell mass to adapt during ageing, which aggravates glucose tolerance. The rat model of protein restriction showed that maternal low-protein diet results in increased susceptibility to insulin resistance in the offspring and that this effect was attributed to reduced  $\beta$ -cell mass due to lower cell proliferation<sup>(42)</sup>. Pinney & Simmons<sup>(43)</sup> studied epigenetic events at the promoter of the gene encoding pancreatic and duodenal homeobox 1 (Pdx-1), a critical

transcriptional factor for  $\beta$ -cell function and development, the expression of which is reduced in intra-uterine growth retardation (IUGR), promoting the development of diabetes in adulthood. IUGR resulted in transcriptional repression of Pdx-1 due to histone deacetylation and a consequent loss of binding of major transcription factors to the Pdx-1 promoter. At the neonatal stage, this epigenetic process is reversible and may define an important developmental window for therapeutic approaches. After birth, histone deacetylation progresses and is followed by a marked decrease in histone H3 lysine 4 (H3K4) trimethylation and a significant increase in dimethylation of histone H3 lysine 9 (H3K9) in IUGR islets. H3K4 trimethylation is usually associated with active gene transcription, while H3K9 dimethylation is usually a repressive chromatin mark. Progression of these histone modifications parallels the progressive decrease in Pdx-1 expression which locks in the silenced state in the IUGR adult pancreas resulting in diabetes<sup>(43)</sup>. Similarly, Raychaudhuri *et al.*<sup>(44)</sup> demonstrated that perinatal nutrient restriction resulting in IUGR leads to histone modifications in skeletal muscle that directly decrease GLUT type 4 (Glut4) gene expression. This effectively creates a metabolic knock-down of this important regulator of peripheral glucose transport and insulin resistance, thereby contributing to adult type 2 diabetes<sup>(44)</sup>.

Besides prenatal under-nutrition models, the metabolic intra-uterine environment may also be modified in the case of prenatal over-nutrition. There is evidence that increased dietary fat intake during pregnancy and lactation predisposes the offspring to develop a metabolic syndrome-like phenotype in adult life. It has been found that maternal high fat feeding results in the offspring having exacerbated adiposity and modified expression of key proteins involved in hepatic insulin sensitivity<sup>(45)</sup>. These offspring also develop endothelial, cardiovascular dysfunction and sex-specific hypertension<sup>(46,47)</sup>.

Maternal fat intake contributes toward non-alcoholic fatty liver disease progression in adult offspring, which is mediated through impaired hepatic mitochondrial metabolism and up-regulated hepatic lipogenesis. It is plausible to speculate that suboptimal nutrition during the developmental period may alter the epigenetic profile of key genes, subsequently leading to persistent modulation in gene transcription and increasing the risk of developing non-alcoholic steatohepatitis in adulthood<sup>(48)</sup>. Perinatal exposure to high-fat, high-sugar diets also results in altered development of the central mesolimbic reward system. These offspring exhibit increased preference for fat, leading to suggestions that perinatal exposure to high-fat, high-sugar foods results in permanent changes within the central reward system that increase the subsequent drive to overconsume palatable foods in postnatal life<sup>(49)</sup>.

Recent evidence indicates that JmjC-domain-containing histone demethylase 2A (JHDM2a), which catalyses removal of H3K9 mono- and dimethylation through Fe- and




$\alpha$ -ketoglutarate-dependent oxidative reactions, regulates metabolic genes related to energy homeostasis including anti-adipogenesis, regulation of fat storage, glucose transport and type 2 diabetes. Mice deficient in JHDM2a develop adult-onset obesity, hypertriglycerolaemia, hypercholesterolaemia, hyperinsulinaemia and hyperleptinaemia, which are hallmarks of the metabolic syndrome. JHDM2a<sup>-/-</sup> mice furthermore exhibit fasted-induced hypothermia indicating reduced energy expenditure and also have a higher RQ indicating less fat utilisation for energy production. These observations may explain the obesity phenotype in these mice. Thus, H3K9 demethylase JHDM2a is a crucial regulator of genes involved in energy expenditure and fat storage, which suggests that it represents a previously unrecognised key regulator of obesity and the metabolic syndrome<sup>(50)</sup>.

Diabetic patients continue to develop inflammation and vascular complications, even when glycaemia is controlled. This process is attributed to a 'hyperglycaemic metabolic memory' based on epigenetic mechanisms. Brasacchio *et al.*<sup>(51)</sup> shows that periods of transient or prior hyperglycaemia lead to various methylation and demethylation events that, when integrated, have an impact on gene activity. These events lead to sustained activation of pro-inflammatory pathways, which are likely to participate in

the progression of diabetic complications. Further understanding of the chromatin remodelling events and how they are linked to ongoing vascular changes in diabetes should lead to better strategies to reduce the burden of diabetes complications<sup>(51)</sup>.

### Microbiota, epigenetics and early postnatal nutrition

It is now becoming clear that the early postnatal environment, including nutrition, is also a vital determinant of adult health (Fig. 1). Environmental exposures such as early infant diet are believed to make an impact on the development and function of gut microbiota<sup>(52)</sup>. The intestinal microbiota plays a critical role in the establishment and maintenance of healthy immune responses. Delayed colonisation of the infant gut with commensal bacteria or alterations in the microbiota profile are suggested to be strong risk factors for the development of immune-mediated chronic disorders such as allergic and autoimmune diseases<sup>(53)</sup>. Solid scientific arguments suggest that immune deviances later in life could be the consequence of an inadequate bacterial pressure on the intestinal mucosa at the early stage. A variety of epigenetic modifications taking place in this early stage could account for the deviant programming of later immunity and overall




**Fig. 1.** The potential role of maternal diet on the development of the metabolic syndrome. Different epigenetic mechanisms may be involved in the long-lasting effects elicited by dietary factors in the development of the main components of the metabolic syndrome: diabetes, obesity, hypertension, dyslipidaemia and CVD.

health status (Fig. 2)<sup>(54)</sup>. While the role of epigenetics in postnatal programming of the neonate remains to be demonstrated, there appears to be a window in which infants are vulnerable<sup>(55)</sup>. Restoring the microbiota profile with a single bacteria species may be effective in the prevention or treatment of allergic and inflammatory diseases, but only if this occurs during the neonatal period. These observations have led to the idea that probiotics, which have the potential to restore the intestinal microbiota balance, may be effective in preventing the development of chronic immune-mediated diseases<sup>(53)</sup>. A probiotic is defined as a living micro-organism which when administered in adequate amounts confers a health benefit on the host<sup>(56)</sup>. The exact mechanisms of action for probiotic bacteria have yet to be fully understood, but it is hypothesised that the biological function of probiotics may be a result of epigenetic modifications that may explain the wide range of the observed effects. An important role for probiotic bacteria is the fermentation of dietary compounds leading to production of SCFA. Studies delineating the effects of probiotics on SCFA production and the epigenetic actions of SCFA will assist in understanding the association between microbiota and allergic or autoimmune disorders. The SCFA butyrate, a main endproduct of microbial fermentation of dietary fibres in the human intestine, plays an important role in the maintenance of intestinal homeostasis and overall health status. The effects exerted by butyrate are multiple from the gut to the peripheral issues with a high potential for a therapeutic use in human medicine<sup>(57)</sup>. Butyrate is part of a class of epigenetic factors known as HDAC inhibitors, with several functions such as anti-inflammatory and anti-carcinogenesis effects. Given the role of bacterial species in the production of SCFA, probiotics may be considered as an alternative approach for the prevention or treatment of chronic inflammatory diseases<sup>(53)</sup>. Intestinal microflora recently also has been implicated in the development of

some metabolic phenotypes, such as obesity and insulin resistance<sup>(58)</sup>. A longitudinal, prospective study in childhood revealed that a combination of early exposures, including delivery mode (vaginal *v.* by caesarean section), maternal pre-pregnancy BMI and antibiotics in infancy (less than 6 months of age), influences the risk of overweight in childhood, evaluated with a follow-up at age 7 years. This effect may potentially be explained by an impact on establishment and diversity of the microbiota<sup>(59)</sup>. Recently, Wang *et al.*<sup>(60)</sup> identified a new direct link between gut flora-dependent metabolism of dietary phosphatidylcholine and CVD pathogenesis, which represents the leading cause of death and morbidity worldwide. These results indicate that an appropriately designed probiotic intervention may serve as a therapeutic strategy for the prevention and treatment of atherosclerotic heart disease and its complications<sup>(60)</sup>. In this regard, it will be important to evaluate in animal models of postnatal dietary manipulation the effects of specific nutrients on methylation and histone modifications, considering that some of the benefits attributed to breast milk may partly be due to the establishment of a beneficial bacterial flora in the gut of milk-fed infants, whichever the origin<sup>(61)</sup>.

## Conclusions

The studies reviewed here suggest that maternal and neonatal diet may have long-lasting effects in the development of non-communicable chronic adulthood diseases, in particular the components of the so-called metabolic syndrome, such as insulin resistance, type 2 diabetes, obesity, dyslipidaemia, hypertension and CVD. Different epigenetic mechanisms may, at least in part, explain the way by which dietary factors in early critical developmental steps might be able to affect the susceptibility to develop metabolic diseases in adulthood. Both maternal under- and over-nutrition may interact with genes controlling lipid and carbohydrate metabolism, thus inducing alterations in epigenetic regulations. Early postnatal environment, including nutrition, may represent a vital determinant of adult health by making an impact on the development and function of gut microbiota. The epigenetic mechanisms elicited by probiotics through the production of SCFA are hypothesised to be the key to understand how they mediate their numerous health-promoting effects from the gut to overall health status. Much of the recent progress in understanding epigenetic phenomena is directly attributable to technologies that allow researchers to pinpoint the genomic location of proteins that package and regulate access to DNA. However, despite recent advances, our knowledge regarding nutritional epigenetics in early life is still limited. Further studies in human subjects using the latest technologies are needed to better understand the use of nutrients or bioactive food components for maintaining our health and preventing diseases through modifiable epigenetic



**Fig. 2.** Offspring phenotype is influenced by genetic programming and by epigenetic regulation of gene expression, elicited by prenatal/neonatal nutrition and intestinal microflora composition in early life.

mechanisms. Moreover, given the plasticity of epigenetic marks and their responsiveness to dietary factors, there is potential for the development of epigenetic marks as biomarkers of health for use in intervention studies.

### Acknowledgements

B. C. R., D. C. M., L. L., B. G., B. P., C. S., N. V., P. A. and A. C. were responsible for the conceptualisation and implementation of the manuscript. B. C. R., D. C. M. and L. L. were responsible for writing the manuscript. All authors reviewed the manuscript and approved it before submission.

This review paper received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

There are no conflicts of interest.

### References

- Burdge GC & Lillycrop KA (2010) Nutrition, epigenetics, and developmental plasticity: implications for understanding human disease. *Annu Rev Nutr* **30**, 315–339.
- Attig L, Gabory A & Junien C (2010) Early nutrition and epigenetic programming: chasing shadows. *Curr Opin Clin Nutr Metab Care* **13**, 284–293.
- Niculescu MD & Lupu DS (2011) Nutritional influence on epigenetics and effects on longevity. *Curr Opin Clin Nutr Metab Care* **14**, 35–40.
- Simmons R (2010) Epigenetics and maternal nutrition: nature *v.* nurture. *Proc Nutr Soc* **70**, 73–81.
- McKay JA & Mathers JC (2011) Diet induced epigenetic changes and their implications for health. *Acta Physiol (Oxf)* **202**, 103–118.
- Zeisel SH (2009) Epigenetic mechanisms for nutrition determinants of later health outcomes. *Am J Clin Nutr* **89**, 1488S–1493S.
- Mathers JC (2007) Early nutrition: impact on epigenetics. *Forum Nutr* **60**, 42–48.
- Choi SW & Friso S (2010) Epigenetics: a new bridge between nutrition and health. *Adv Nutr* **1**, 8–16.
- Stegers-Theunissen RP, Obermann-Borst SA, Kremer D, *et al.* (2009) Periconceptional maternal folic acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young child. *PLoS One* **4**, e7845.
- Sinclair KD, Allegrucci C, Singh R, *et al.* (2007) DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. *Proc Natl Acad Sci U S A* **104**, 19351–19356.
- Zeisel SH (2011) Nutritional genomics: defining the dietary requirement and effects of choline. *J Nutr* **141**, 531–534.
- Mehedint MG, Craciunescu CN & Zeisel SH (2010) Maternal dietary choline deficiency alters angiogenesis in fetal mouse hippocampus. *Proc Natl Acad Sci U S A* **107**, 12834–12839.
- Kanai Y & Hirohashi S (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. *Carcinogenesis* **28**, 2434–2442.
- Waterland RA (2009) Is epigenetics an important link between early life events and adult disease? *Horm Res* **71**, 13–16.
- Ficz G, Branco MR, Seisenberger S, *et al.* (2011) Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature* **473**, 398–402.
- Delage B & Dashwood RH (2008) Dietary manipulation of histone structure and function. *Annu Rev Nutr* **28**, 347–366.
- Dashwood RH & Ho E (2007) Dietary histone deacetylase inhibitors: from cells to mice to man. *Semin Cancer Biol* **17**, 363–369.
- Lewis BP, Shih IH, Jones-Rhoades MW, *et al.* (2003) Prediction of mammalian microRNA targets. *Cell* **115**, 787–798.
- Lim LP, Lau NC, Garrett-Engele P, *et al.* (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* **433**, 769–773.
- Chuang JC & Jones PA (2007) Epigenetics and microRNAs. *Pediatr Res* **61**, 24R–29R.
- Iorio MV, Piovani C & Croce CM (2010) Interplay between microRNAs and the epigenetic machinery: an intricate network. *Biochim Biophys Acta* **1799**, 694–701.
- Salerno E, Scaglione BJ, Coffman FD, *et al.* (2009) Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. *Mol Cancer Ther* **8**, 2684–2692.
- Sun M, Estrov Z, Ji Y, *et al.* (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. *Mol Cancer Ther* **7**, 464–473.
- Yang J, Cao Y, Sun J, *et al.* (2010) Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. *Med Oncol* **27**, 1114–1118.
- Weiss FU, Marques IJ, Woltering JM, *et al.* (2009) Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. *Gastroenterology* **137**, 2136–2145.e7.
- Pogribny IP, Starlard-Davenport A, Tryndyak VP, *et al.* (2010) Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain specific susceptibility to dietary nonalcoholic steatohepatitis in mice. *Lab Invest* **90**, 1437–1446.
- Cirera S, Birck M, Busk PK, *et al.* (2010) Expression profiles of miRNA-122 and its target CAT1 in minipigs (*Sus scrofa*) fed a high cholesterol diet. *Comp Med* **60**, 136–141.
- Ponting CP, Oliver PL & Reik W (2009) Evolution and functions of long noncoding RNAs. *Cell* **136**, 629–641.
- Godfrey KM & Barker DJ (2001) Fetal programming and adult health. *Public Health Nutr* **4**, 611–624.
- Bertram CE & Hanson MA (2001) Animal models and programming of the metabolic syndrome. *Br Med Bull* **60**, 103–121.
- Armitage JA, Khan IY, Taylor PD, *et al.* (2004) Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals? *J Physiol* **561**, 355–377.
- Armitage JA, Taylor PD & Poston L (2005) Experimental models of developmental programming: consequences of exposure to an energy rich diet during development. *J Physiol* **565**, 3–8.
- Lillycrop KA, Phillips ES, Torrens C, *et al.* (2008) Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR $\alpha$  promoter of the offspring. *Br J Nutr* **100**, 278–282.
- Lillycrop KA, Slater-Jefferies JL, Hanson MA, *et al.* (2007) Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. *Br J Nutr* **97**, 1064–1073.

35. Sandovici I, Smith NH, Nitert MD, *et al.* (2011) Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. *Proc Natl Acad Sci U S A* **108**, 5449–5454.
36. Thone-Reineke C, Kalk P, Dorn M, *et al.* (2006) High-protein nutrition during pregnancy and lactation programs blood pressure, food efficiency, and body weight of the offspring in a sex-dependent manner. *Am J Physiol Regul Integr Comp Physiol* **291**, R1025–R1030.
37. Maurer AD & Reimer RA (2011) Maternal consumption of high-prebiotic fibre or -protein diets during pregnancy and lactation differentially influences satiety hormones and expression of genes involved in glucose and lipid metabolism in offspring in rats. *Br J Nutr* **105**, 329–338.
38. Ong KK (2007) Catch-up growth in small for gestational age babies: good or bad? *Curr Opin Endocrinol Diabetes Obes* **14**, 30–34.
39. Xita N & Tsatsoulis A (2010) Fetal origins of the metabolic syndrome. *Ann N Y Acad Sci* **1205**, 148–155.
40. Cianfarani S, Germani D & Branca F (1999) Low birth weight and adult insulin resistance: the 'catch-up growth' hypothesis. *Arch Dis Child Fetal Neonatal* **81**, F71–F73.
41. Garofano A, Czernichow P & Bréant B (2000) Impaired  $\beta$ -cell regeneration in perinatally malnourished rats: a study with STZ. *FASEB J* **14**, 2611–2617.
42. Petrik J, Reusens B, Arany E, *et al.* (1999) A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. *Endocrinology* **140**, 4861–4873.
43. Pinney SE & Simmons RA (2010) Epigenetic mechanisms in the development of type 2 diabetes. *Trends Endocrinol Metab* **21**, 223–229.
44. Raychaudhuri N, Raychaudhuri S, Thamocharan M, *et al.* (2008) Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. *J Biol Chem* **283**, 13611–13626.
45. Buckley AJ, Keserü B, Briody J, *et al.* (2005) Altered body composition and metabolism in the male offspring of high fat-fed rats. *Metabolism* **54**, 500–507.
46. Khan IY, Taylor PD, Dekou V, *et al.* (2003) Gender-linked hypertension in offspring of lard-fed pregnant rats. *Hypertension* **41**, 168–175.
47. Khan IY, Dekou V, Douglas G, *et al.* (2005) A high-fat diet during rat pregnancy or suckling induces cardiovascular dysfunction in adult offspring. *Am J Physiol Regul Integr Comp Physiol* **288**, R127–R133.
48. Bruce KD, Cagampang FR, Argenton M, *et al.* (2009) Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. *Hepatology* **50**, 1796–1808.
49. Ong ZY & Muhlhausler BS (2011) Maternal 'junk-food' feeding of rat dams alters food choices and development of the mesolimbic reward pathway in the offspring. *FASEB J* **25**, 2167–2179.
50. Inagaki T, Tachibana M, Magoori K, *et al.* (2009) Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice. *Genes Cells* **14**, 991–1001.
51. Brasacchio D, Okabe J, Tikellis C, *et al.* (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. *Diabetes* **58**, 1229–1236.
52. BerniCanani R, Passariello A, Buccigrossi V, *et al.* (2008) The nutritional modulation of the evolving intestine. *J Clin Gastroenterol* **42**, Suppl. 3, S197–S200.
53. Licciardi PV, Wong SS, Tang ML, *et al.* (2010) Epigenome targeting by probiotic metabolites. *Gut Pathog* **2**, 24.
54. Langhendries JP, Maton P, François A, *et al.* (2010) Implementation of the intestinal micro flora in the early stage and adequate immunity later on (article in French). *Arch Pediatr* **17**, Suppl. 3, S110–S118.
55. Wiedmeier JE, Joss-Moore LA, Lane RH, *et al.* (2011) Early postnatal nutrition and programming of the preterm neonate. *Nutr Rev* **69**, 76–82.
56. Brown AC & Valiere A (2004) Probiotics and medical nutrition therapy. *Nutr Clin Care* **7**, 56–58.
57. Berni Canani R, Di Costanzo M, Leone L, *et al.* (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol* **17**, 1519–1528.
58. Dumas ME, Barton RH, Toye A, *et al.* (2006) Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. *Proc Natl Acad Sci U S A* **103**, 12511–12516.
59. Ajslev TA, Andersen CS, Gamborg M, *et al.* (2011) Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. *Int J Obes (Lond)* **35**, 522–529.
60. Wang Z, Klipfell E, Bennett BJ, *et al.* (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **472**, 57–63.
61. Poroyko V, White JR, Wang M, *et al.* (2010) Gut microbial gene expression in mother-fed and formula-fed piglets. *PLoS One* **5**, e12459.